ArticleContemporary clinical trials2022

Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.

Michael T Eadon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.